These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 9217190)
1. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Socié G; Cahn JY; Carmelo J; Vernant JP; Jouet JP; Ifrah N; Milpied N; Michallet M; Lioure B; Pico JL; Witz F; Molina L; Fischer A; Bardou VJ; Gluckman E; Reiffers J Br J Haematol; 1997 Jun; 97(4):865-70. PubMed ID: 9217190 [TBL] [Abstract][Full Text] [Related]
2. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Socié G; Sélimi F; Sedel L; Frija J; Devergie A; Esperou Bourdeau H; Ribaud P; Gluckman E Br J Haematol; 1994 Mar; 86(3):624-8. PubMed ID: 8043445 [TBL] [Abstract][Full Text] [Related]
3. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Enright H; Haake R; Weisdorf D Am J Med; 1990 Dec; 89(6):733-8. PubMed ID: 2252042 [TBL] [Abstract][Full Text] [Related]
4. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM). Michallet M; Tanguy ML; Socié G; Thiébaut A; Belhabri A; Milpied N; Reiffers J; Kuentz M; Cahn JY; Blaise D; Demeocq F; Jouet JP; Michallet AS; Ifrah N; Vilmer E; Molina L; Michel G; Lioure B; Cavazzana-Calvo M; Pico JL; Sadoun A; Guyotat D; Attal M; Curé H; Bordigoni P; Sutton L; Buzyn-Veil A; Tilly M; Keoirruer N; Feguex N Br J Haematol; 2000 Feb; 108(2):400-7. PubMed ID: 10691873 [TBL] [Abstract][Full Text] [Related]
5. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study. Bordigoni P; Esperou H; Souillet G; Pico J; Michel G; Lacour B; Reiffers J; Sadoun A; Rohrlich P; Jouet JP; Milpied N; Lutz P; Plouvier E; Cornu G; Vannier JP; Gandemer V; Rubie H; Gratecos N; Leverger G; Stephan JL; Boutard P; Vernant JP Br J Haematol; 1998 Aug; 102(3):656-65. PubMed ID: 9722290 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838 [TBL] [Abstract][Full Text] [Related]
7. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768 [TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle. Jourdan E; Maraninchi D; Reiffers J; Archimbaud E; Michallet M; Harousseau JL; Ifrah N; Rio B; Guyotat D; Guilhot F Leukemia; 1995 Jun; 9(6):1068-71. PubMed ID: 7596171 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387 [TBL] [Abstract][Full Text] [Related]
10. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM). Jourdan E; Maraninchi D; Reiffers J; Gluckman E; Rio B; Jouet JP; Michallet M; Molina L; Archimbaud E; Harousseau JL; Ifrah N; Attal M; Guilhot F; Kuentz M; Guyotat D; Pico JL; Dauriac C; Legros M; Dreyfus F; Bordigoni P; Leblond V; Gratecos N; Varet B; Auzanneau C; Blaise D Bone Marrow Transplant; 1997 May; 19(9):875-81. PubMed ID: 9156260 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle. Dhedin N; Giraudier S; Gaulard P; Esperou H; Ifrah N; Michallet M; Milpied N; Rio B; Cahn JY; Molina L; Laporte JL; Guilhot F; Kuentz M Br J Haematol; 1999 Oct; 107(1):154-61. PubMed ID: 10520036 [TBL] [Abstract][Full Text] [Related]
12. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Li X; Brazauskas R; Wang Z; Al-Seraihy A; Baker KS; Cahn JY; Frangoul HA; Gajewski JL; Hale GA; Hsu JW; Kamble RT; Lazarus HM; Marks DI; Maziarz RT; Savani BN; Shah AJ; Shah N; Sorror ML; Wood WA; Majhail NS Biol Blood Marrow Transplant; 2014 Apr; 20(4):587-92. PubMed ID: 24388803 [TBL] [Abstract][Full Text] [Related]
13. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: a report from the Groupe d'Etude des Greffes de Moelle Osseuse. Michel G; Gluckman E; Blaise D; Esperou-Bourdeau H; Vernant JP; Kuentz M; Bordigoni P; Milpied N; Rubie H; Thuret I J Clin Oncol; 1992 Dec; 10(12):1865-9. PubMed ID: 1453201 [TBL] [Abstract][Full Text] [Related]
14. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y; Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. Robin M; Guardiola P; Dombret H; Baruchel A; Esperou H; Ribaud P; Devergie A; Gluckman E; Socié G Bone Marrow Transplant; 2003 May; 31(10):877-87. PubMed ID: 12748664 [TBL] [Abstract][Full Text] [Related]
16. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218 [TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
18. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Mohty M; Labopin M; Balère ML; Socié G; Milpied N; Tabrizi R; Ifrah N; Hicheri Y; Dhedin N; Michallet M; Buzyn A; Cahn JY; Bourhis JH; Blaise D; Raffoux C; Espérou H; Yakoub-Agha I Leukemia; 2010 Nov; 24(11):1867-74. PubMed ID: 20882046 [TBL] [Abstract][Full Text] [Related]
20. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Pigneux A; Tanguy ML; Michallet M; Jouet JP; Kuentz M; Vernant JP; Milpied N; Ifrah N; Cahn JY; Gratecos N; Reman O; Cure H; Caillot D; Witz F; Pillier-Loriette C; Tron P; Reiffers J; Br J Haematol; 2002 Jan; 116(1):193-201. PubMed ID: 11841417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]